“…MiRNA microarray investigation revealed that 44 miRNAs were downregulated and 49 miRNAs were upregulated throughout the early, middle, and late phases of murine osteoclastogenesis (Table 1) [15]; miR-29, miR-31-5p, hsa-miR-422a, hsa-miR-148a-3p, miR-183-5p, miR-214-3p, and miR-9718 were found to be expressed in a way that promoted osteoclastogenesis, while miR-7b-5p, miR-26a-5p, miR-34a-5p, miR-124-3p, miR-125a-5p, miR-146a-5p, miR-218-5p, and miR-503-5p were found to be expressed in a way that inhibited osteoclastogenesis. Furthermore, three miRNAs-miR-21-5p, hsa-miR-133a-3p, and miR-223-3p-were demonstrated to have both promotion and inhibitory effects [6]. In a recent study, patients with multiple myeloma and with or without ONJ had their miRNA levels examined and it was demonstrated that miRNAs miR-16-1, miR-21, miR-23a, miR-28, miR-101-1, miR-124-1, miR-129, miR-139, miR-145, miR-149, miR-202, miR-221, miR-424, and miR-520 were considerably overexpressed in ONJ patients compared to controls.…”